Rocket Pharmaceuticals, Inc. financial data

Symbol
RCKT, RCKTW on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Fifth Avenue, Suite 7530, New York, NY
State of incorporation
Delaware
Fiscal year end
December 31
Former names
INOTEK PHARMACEUTICALS CORP (to 12/22/2017)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 959 % -2.37%
Debt-to-equity 13.5 % +2.35%
Return On Equity -54.5 % +5.81%
Return On Assets -48 % +6.07%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91M shares +13%
Common Stock, Shares, Outstanding 91M shares +13%
Entity Public Float 1.2B USD +86.2%
Common Stock, Value, Issued 910K USD +13%
Weighted Average Number of Shares Outstanding, Basic 93.7M shares +16.5%
Weighted Average Number of Shares Outstanding, Diluted 93.7M shares +16.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 180M USD -5.76%
General and Administrative Expense 89.6M USD +33.1%
Operating Income (Loss) -270M USD -4.36%
Net Income (Loss) Attributable to Parent -253M USD -1.91%
Earnings Per Share, Basic -2.77 USD/shares +16.3%
Earnings Per Share, Diluted -2.77 USD/shares +16.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 38.6M USD -14.4%
Cash, Cash Equivalents, and Short-term Investments 279M USD -9.19%
Assets, Current 293M USD -6.2%
Property, Plant and Equipment, Net 39.5M USD +19.9%
Operating Lease, Right-of-Use Asset 4.55M USD +4.74%
Intangible Assets, Net (Excluding Goodwill) 25.2M USD -2.23%
Goodwill 39.2M USD 0%
Assets 446M USD -3.33%
Employee-related Liabilities, Current 7.29M USD +21.3%
Liabilities, Current 37.6M USD +9.45%
Operating Lease, Liability, Noncurrent 3.57M USD +16%
Other Liabilities, Noncurrent 1.25M USD -39.9%
Liabilities 61.8M USD +5.04%
Accumulated Other Comprehensive Income (Loss), Net of Tax -218K USD +69.8%
Retained Earnings (Accumulated Deficit) -1.09B USD -30.2%
Stockholders' Equity Attributable to Parent 385M USD -4.55%
Liabilities and Equity 446M USD -3.33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -56.9M USD +1.22%
Net Cash Provided by (Used in) Financing Activities 1.18M USD -93.5%
Net Cash Provided by (Used in) Investing Activities 35M USD
Common Stock, Shares Authorized 180M shares +50%
Common Stock, Shares, Issued 91M shares +13%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40M USD -13.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 108M USD +18.9%
Operating Lease, Liability 4.6M USD +6.76%
Payments to Acquire Property, Plant, and Equipment 2.04M USD -32.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -253M USD -1.72%
Lessee, Operating Lease, Liability, to be Paid 6.24M USD +2.7%
Property, Plant and Equipment, Gross 57.1M USD +28.6%
Operating Lease, Liability, Current 1.03M USD -16.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.01M USD +86.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1M USD +10.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.64M USD -7.18%
Lessee, Operating Lease, Liability, to be Paid, Year Three 759K USD +39.3%
Deferred Tax Assets, Operating Loss Carryforwards 45.3M USD +34.4%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 522K USD +3.16%
Operating Lease, Payments 333K USD +27.6%
Additional Paid in Capital 1.48B USD +18.9%
Depreciation, Depletion and Amortization 1.8M USD +50%
Share-based Payment Arrangement, Expense 41.8M USD +14.5%
Interest Expense 1.88M USD +0.64%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%